Navigation Links
Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB
Date:1/9/2009

DUBLIN, Ireland, January 9 /PRNewswire/ -- Azur Pharma Limited ("Azur Pharma") today announced that it licensed the exclusive U.S. marketing rights for Niravam(R) (alprazolam orally disintegrating tablets), Parcopa(R) (carbidopa-levodopa orally disintegrating tablets), Kemstro(TM) (baclofen orally disintegrating tablets) and Fluxid(TM) (famotidine orally disintegrating tablets) from UCB (Euronext: UCB). Financial terms were not disclosed.

Niravam, Parcopa and Kemstro are central nervous system ("CNS") products. Azur Pharma's CNS business currently markets FazaClo(R) in the U.S. for the management of severely ill schizophrenic patients who fail to respond adequately to standard schizophrenia drug treatments. FazaClo is supplied as an innovative orally disintegrating tablet that uses proprietary formulation technologies licensed from CIMA Labs Inc. ("CIMA"), a subsidiary of Cephalon Inc (NASDAQ: CEPH).

Mr Seamus Mulligan, Chairman and Chief Executive of Azur stated, "We are pleased to add these valuable products to our portfolio. In particular, Niravam, Parcopa and Kemstro represent a broadening of our CNS franchise and are consistent with our approach of improving our products through the application of value added drug delivery technologies."

Niravam and Parcopa have been commercially available in the U.S. since 2005 and 2004, respectively. There is one approved generic competitor to Parcopa. Two ANDAs to Niravam have been filed with the FDA. Kemstro and Fluxid are both FDA approved but not yet commercially available in the U.S.

About Azur Pharma

Azur is a privately held pharmaceutical company dedicated to enhancing patients' lives by developing and marketing pharmaceutical products in specialist therapeutic areas. Azur's strategy is to identify, evaluate, selectively acquire and enhance the value of late stage development and approved pharmaceutical products. (Website: http://www.azurpharma.com )


'/>"/>
SOURCE Azur Pharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 25, 2017 , ... LABS, Inc. (LABS) announced ... added to its extensive test menu: Nucleic Acid Testing (NAT) for ZIKV; and Enzyme ... only able to offer NAT screening for blood donors under an Investigational New Drug ...
(Date:4/26/2017)... ... April 26, 2017 , ... NextSteps ... and North America this May on the following dates: , ?    London, ... Taylor, Chairman of the Learning and Performance Institute will be the opening ...
(Date:4/26/2017)... April 26, 2017  Genisphere LLC, provider of ... signed a collaborative and sponsored research agreement with ... Muro . The overall goal of the partnership ... various 3DNA designs and formulations after in ... of the vasculature as well as inflammatory responses, ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... of Common Lisp (CL) development tools, and market leader for Semantic Graph ... performance enhancements now available within the most effective system for developing and deploying ...
Breaking Biology Technology:
(Date:4/17/2017)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... 2016 Annual Report on Form 10-K on Thursday April 13, 2017 ... ... Investor Relations section of the Company,s website at http://www.nxt-id.com  under ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
Breaking Biology News(10 mins):